Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia
06 12월 2023 - 6:01AM
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage
biopharmaceutical company focused on developing novel drugs for
immuno-inflammatory diseases, today announced an exclusive patent
license agreement with Sun Pharmaceutical Industries, Inc. (Sun
Pharma).
Under the license agreement, Aclaris granted Sun Pharma
exclusive rights under certain patents for the use of
deuruxolitinib, Sun Pharma’s JAK inhibitor, or other isotopic forms
of ruxolitinib, to treat alopecia areata (AA) or androgenetic
alopecia (AGA). The agreement includes an upfront payment of $15
million, regulatory and commercial milestones, and royalties.
Aclaris exclusively licenses the patents from a third party, and
has separate contractual obligations under which it owes a portion
of the consideration received from Sun Pharma.
“We are pleased to announce this patent license agreement with
Sun Pharma, which represents our second out-license for this patent
portfolio,” stated James Loerop, Chief Business Officer of
Aclaris.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing a pipeline of novel drug candidates to address
the needs of patients with immuno-inflammatory diseases who lack
satisfactory treatment options. The company has a multi-stage
portfolio of drug candidates powered by a robust R&D engine
exploring protein kinase regulation. For additional information,
please visit www.aclaristx.com.
Aclaris Therapeutics Contact:
Robert A. Doody Jr.Senior Vice President, Investor
Relations484-639-7235rdoody@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Aclaris Therapeutics (NASDAQ:ACRS)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024